Mauna Kea Technologies Sa Class O · EURONEXT:ALMKT

Mauna Kea Technologies Sa Class O — Q2 & H1 2023 Earnings Presentation

16 slides from Mauna Kea Technologies Sa Class O's earnings presentation, Jul 20, 2023

  1. Slide 1: Q2 & H1 2023 Business Update

    Q2 & H1 2023 Business Update July 20, 2023

  2. Slide 2: Disclaimer

    Disclaimer • This document has been prepared by Mauna Kea Technologies (the "Company") and is provided for information purposes only. • The information and opinions contained in this document speak only as of the date of this document and may be updated, supplemented, revised, verified or amended, a

  3. Slide 3: Speakers

    Speakers Sacha Loiseau, Ph.D. Côme de La Tour du Pin Chairman and Chief Financial Officer Chief Executive Officer © 2023 Mauna Kea Technologies 3

  4. Slide 4: See Cells. Change Lives. Mission

    See Cells. Change Lives. By creating the first platform to image the human body at the cellular level, we’ve changed the way physicians see and treat their patients Mission With Cellvizio®, our advanced cellular imaging platform, we provide partners and providers with cutting edge technologies to tr

  5. Slide 5: The Future of Cellvizio is Built on Strong Pillars

    The Future of Cellvizio is Built on Strong Pillars ® Unique and Extensive Strong pipeline of Long-standing Strong intellectual differentiated knowledge of potential strategic collaborations with property portfolio imaging platform procedures partnerships industry leaders • Proprietary imaging • 250+

  6. Slide 6: Huge market opportunities

    Huge market opportunities Urology GI / IBD / IBS (Endourology / Surgery) $2.2B+ High $1.0B $1.0B /yr /yr /yr GI / Barrett’s Esophagus & $0.5B Stomach cancer $0.5B/yr $100M /yr /yr MARKET SIZE Low Interventional Neurosurgery GI / Pancreatic cysts Pulmonology MATURITY OF APLLICATION < ONCOLOGY < IBD/I

  7. Slide 7: Extensive pipeline of indications for potential strategic partnerships

    Extensive pipeline of indications for potential strategic partnerships CLINICAL REGULATORY IN COMMERCIAL APPLICATION ECOSYSTEM DEVELOPMENT APPROVAL MARKET PARTNERSHIP PANCREATIC KISTS #needles #AI GLOBAL DIRECT OPEN ESOPHAGEAL & #endoscopy STOMACH CANCERS GLOBAL DIRECT OPEN #AI ONCOLOGY LUNG CANCER

  8. Slide 8: An increasingly sophisticated platform

    An increasingly sophisticated platform MOLECULAR CANCER IMAGING ROBOTIC ASSISTED IMAGING X ARTIFICIAL INTELLIGENCE BUILD CELLVIZIO IMAGING DATASETS • In vivo endoscopic visualization of • Integrated navigation targeted cancer cells and data capture Cellvizio next- • Advanced prototype generation adv

  9. Slide 9: Main achievements in the first half of 2023

    Main achievements in the first half of 2023 CORPORATE ACTIVITY PARTNERSHIP CELLVIZIO Strengthened Excellent Business Delivering on Our Platform Leadership Team Performance Strategy enhancement Strong acceleration of Launch of JV with Tasly Appointment of a Chief sales growth notably in in China Laun

  10. Slide 10: Financials

    FINANCIALS © 2023 Mauna Kea Technologies 10

  11. Slide 11: Strong Revenue Growth in Q2 and H1 2023

    Strong Revenue Growth in Q2 and H1 2023 Q2 2023 Revenue in Q2 and H1 2023 vs 2022 In thousands of euros €6.8m +77% €7,000 revenue growth driven by a +100% increase in sales in the United States and by licensing €5,250 €3,301 revenues from the JV with Tasly €3,500 €2.7m H1 2023 €499 €1,750 €3,397 €3,

  12. Slide 12: Sales by Segment in Q2 2023

    Sales by Segment in Q2 2023 Systems Strong growth in the United States and Europe, with 4 €699 systems sold, despite the negative impact from the +93% transfer of Chinese business to the JV with Tasly €363 Consumables Strong acceleration in the US PPU business, up 50% €1,100 despite fluorescein suppl

  13. Slide 13: Sales by Geography in Q2 2023

    Sales by Geography in Q2 2023 United States Excellent momentum in the United States, with sales €1,669 doubling, driven both by systems and probes, and by +100% the acceleration of the PPU business €833 €481 EU & RoW Business boosted by system sales, including the €358 +34% installation of a Cellviz

  14. Slide 14: Outlook

    OUTLOOK © 2023 Mauna Kea Technologies 14

  15. Slide 15: The Group's priorities

    The Group's priorities Drive Business Increase Ensure Build High-Value Momentum Operational Technological Partnerships Performance Excellence Intensify the adoption Develop new features Establish high-profile of the next-generation twice a year Optimize cost structure JV in China Cellvizio Integrate

  16. Slide 16: Q&A

    Q&A © 2023 Mauna Kea Technologies 16

Mauna Kea Technologies — Q2 & H1 2023 Earnings Presentation on 6ix